Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SBB on its offer for Hemfosa
Mandate

Vinge advises SBB on its offer for Hemfosa

November 15, 2019 Capital Markets and Public M&A

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has announced a recommended public offer to the shareholders of Hemfosa Fastigheter AB (publ) (“Hemfosa”) to tender all their shares in Hemfosa to SBB.

The total offer consideration consists of a combination of cash and SBB shares. At announcement, the total offer value for all Hemfosa shares is approximately SEK 23.5 billion. SBB is a major Nordic social infrastructure property company with a property portfolio with a market value of SEK 30.8 billion as of 30 September 2019. SBB’s Class B and Class D common shares are listed in Nasdaq Stockholm, Large Cap.

SBB has retained Vinge as legal advisor. The Vinge team mainly consist of Jesper Schönbeck, Erik Sjöman, Rikard Lindahl, Malte Hedlund, Boris Kotur and Clara Sohlberg, and Albert Wållgren, Ludvig Wettergren and Axel Jansson (on finance matters), Trine Osen Bergqvist and Johan Wahlbom (on competition matters) and Maria Schultzberg and Victor Ericsson (on tax matters).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025